Shire Combination with Baxalta - Shire plc and Baxalta Incorporated announced their combination which would create a global biotechnology company with over EUR20bn in revenues. Rare diseases are expected to account for 65% of combined revenues and the combined portfolio will include over 30 recent and planned launches. The value of the offer, as of Shire's 8th January ADS price, represented a 37.5% premium as to Baxalta's unaffected share price as at the first public announcement date. The parties expect to close the transaction mid-2016. (Slaughter and May advised Shire plc).
Financial Centre : London Law Firm : Slaughter and May Lawyer : Martin Hattrell
Practice Area : Corporate and M&A Classification : Strategic Buyer Acquisitions Sub-classification : Public Company - Recommended Offer Industry : Pharmaceuticals & Biotechnology
Advised Party : Acquiror Value USD Equiv: 5001.00-10000.00M
Target Company Jurisdiction: : United States Acquiror Jurisdiction: : United Kingdom
Editorial
13 Jan 2016 Shire Combination with Baxalta
Shire Combination with Baxalta - Shire plc and Baxalta Incorporated announced their combination which would create a global biotechnology company with over EUR20bn in revenues. Rare diseases are expected to account for 65% of combined revenues and the combined portfolio will include over 30 recent and planned launches. The value of the offer, as of Shire's 8th January ADS price, represented a 37.5% premium as to Baxalta's unaffected share price as at the first public announcement date. The parties expect to close the transaction mid-2016. (Slaughter and May advised Shire plc).
Financial Centre : London
Law Firm : Slaughter and May
Lawyer : Martin Hattrell
Practice Area : Corporate and M&A
Classification : Strategic Buyer Acquisitions
Sub-classification : Public Company - Recommended Offer
Industry : Pharmaceuticals & Biotechnology
Advised Party : Acquiror
Value USD Equiv: 5001.00-10000.00M
Target Company Jurisdiction: : United States
Acquiror Jurisdiction: : United Kingdom